<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026632</url>
  </required_header>
  <id_info>
    <org_study_id>C-21-01</org_study_id>
    <nct_id>NCT05026632</nct_id>
  </id_info>
  <brief_title>NPI-002 Intravitreal Implant for the Delay of Cataract Progression</brief_title>
  <official_title>Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nacuity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nacuity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and efficacy NPI-002 intravitreal implants post&#xD;
      vitrectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lens Densitometry</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Single NPI-002 Intravitreal Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double NPI-002 Intravitreal Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPI-002 Intravitreal Implant</intervention_name>
    <description>Implant inserted during vitrectomy.</description>
    <arm_group_label>Double NPI-002 Intravitreal Implant</arm_group_label>
    <arm_group_label>Single NPI-002 Intravitreal Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Indicated for vitrectomy&#xD;
&#xD;
          2. Natural Lens in place at time of vitrectomy&#xD;
&#xD;
          3. Some cataract present as assessed pre-operatively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous intraocular surgery in study eye&#xD;
&#xD;
          2. Clear zonular weakness or defects / coloboma&#xD;
&#xD;
          3. Not on stable dose of medications for other conditions.&#xD;
&#xD;
          4. Need for oral corticosteroids during study participation.&#xD;
&#xD;
          5. Evidence or history of diabetic retinopathy, glaucoma, uveitis, or ocular ischemia.&#xD;
&#xD;
          6. Current smoker&#xD;
&#xD;
          7. Use of supplemental oxygen&#xD;
&#xD;
          8. Diabetes&#xD;
&#xD;
          9. Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation.&#xD;
&#xD;
         10. Sensitivity to thiol compounds.&#xD;
&#xD;
         11. Participation in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jami R Kern, PhD</last_name>
    <phone>817-291-4232</phone>
    <email>jami@nacuity.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

